This application claims the benefit of US Provisional Application No. 61 / 716,270, filed Oct. 19, 2012, which is related to the monitoring of diffuse large B-cell lymphoma monitoring with peripheral blood samples. The application is incorporated herein by reference in its entirety.

摘要

The present invention is directed to a sequencing-based method for monitoring minimal residual disease of diffuse large B-cell lymphoma (DLBCL) with one or more clonotypes correlated with the disorder. In some embodiments, such methods comprise the following steps: (a) obtaining a sample of peripheral blood from a patient; (b) amplifying a nucleic acid molecule comprising a recombinant DNA sequence derived from an immunoglobulin gene from the sample. (C) sequencing the amplified nucleic acid molecules to form a clonotype profile; and (d) from the clonotype profile, one or more patient-specific clonotypes correlated with DLBCL and these Determining the presence and / or level of a phylogenetic clonotype. [Selection figure] None